Par launches authorized generic of Noxafil

Par, an Endo company, has begun shipping the authorized generic version of Merck's Noxafil  (posaconazole) 200 mg/5 ml oral suspension.

Noxafil is an azole antifungal agent.

"Our partnership with Merck underscores our reputation as an industry-leading supplier," said Scott Sims, senior vice president and general manager, injectable solutions and generics at Endo. "This newly available Noxafil AG dosage form is the latest addition to our generics portfolio—providing patient access to high-quality, lower-cost treatment options."

[Read more: Endo acquires Nevakar’s injectable product candidates]

Endo subsidiary Endo Ventures entered into an exclusive U.S. supply and distribution agreement with a subsidiary of Merck & Co. of Rahway, N.J., allowing Par to launch and distribute an authorized generic version of the product. The agreement also included the authorized generic version of Noxafil delayed-release tablets, 100 mg, which launched in 2019.

[Read more: Par launches generic Pylera]